<DOC>
	<DOCNO>NCT00246636</DOCNO>
	<brief_summary>The purpose OM5/LOV111859 evaluate efficacy safety Omacor ( omega-3-acid ethyl ester ) add-on therapy Antara ( fenofibrate ) diet treatment patient high triglyceride . The purpose OM5X/LOV111860 ass continue efficacy safety adjunctive Lovaza ( omega-3-acid ethyl ester ) therapy hypertriglyceridemic subject treat fenofibrate lowering serum triglyceride ( TG ) level .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Omacor ( Omega-3-acid Ethyl Esters ) Add-on Therapy Hypertriglyceridemic Subjects Treated With Antara ( Fenofibrate ) Followed 8-week Extension</brief_title>
	<detailed_description>Three study comprise OM5 Program - Study OM5 / LOV111859 ( double-blind study ) OM5X / LOV111860 ( 1st open-label extension ) part list ClinicalTrials.gov - NCT00246636 . - Study OM5XX / LOV111821 ( 2nd open-label extension ) list separate listing ClinicalTrials.gov - NCT00891293</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>For OM5/LOV111858 Men woman age 1879 year , inclusive Triglyceride level 500 mg/dL &lt; 1300 mg/dL Body mass index 25 43 kg/m2 Willingness follow lowsaturated fat diet study period maintain current physical activity level Normally active good health basis medical history , brief physical examination , electrocardiogram , routine laboratory test Provide write informed consent authorization protect health information disclosure Sensitivity fibrate drug omega3 fatty acid Lipoprotein lipase impairment apo C2 deficiency Type III hyperlipidemia History pancreatitis Recent history certain kidney , liver , lung , gastrointestinal disease cancer ( except nonmelanoma skin cancer ) Poorly control diabetes mellitus Type 1 diabetes Pregnant lactating female . Women childbearing potential use medically approve method contraception . Use certain type hormone , anticonvulsant drug , immunologic drug , antibiotic , antifungal antiviral drug , cardiac drug Use isotretinoin ( Accutane ) Use warfarin ( Coumadin ) For OM5X/LOV111859 Subjects include study meet follow criterion : 1 . Satisfied inclusion exclusion criterion prior throughout previous OM5 study correspond approve protocol deviation 2 . Successfully complete previous OM5 doubleblind study Week 8 3 . Provided write informed consent Week 8 clinic visit OM5 doubleblind study ( i.e. , Visit 1X OM5X extension study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Very high triglyceride</keyword>
	<keyword>omega-3-acid ethyl ester</keyword>
	<keyword>fenofibrate</keyword>
	<keyword>Lovaza</keyword>
</DOC>